SOURCE: CoMentis


July 12, 2010 08:00 ET

Terence A. Kelly, Ph.D., Joins CoMentis as Senior Vice President for Discovery and Preclinical Development

SOUTH SAN FRANCISCO, CA--(Marketwire - July 12, 2010) -  CoMentis, Inc., a privately held biopharmaceutical company, today announced that Terence A. Kelly, Ph.D., has joined the company as Senior Vice President for Discovery and Preclinical Development, effective immediately. Dr. Kelly joins CoMentis after nearly 20 years at Boehringer Ingelheim, a leading research-driven pharmaceutical company, most recently as Vice President of Chemistry. At CoMentis, he has responsibility for the Oklahoma City Research group. 

"Terry's international pharmaceutical experience in early-stage drug development, along with his medicinal chemistry expertise, are invaluable assets to CoMentis at this time," stated W. Scott Harkonen, M.D., CoMentis President and Chief Executive Officer. 

Since joining Boehringer Ingelheim in 1990, Dr. Kelly contributed to multiple projects that reached advanced clinical trials in the areas of HIV/AIDS, psoriasis and rheumatoid arthritis. Beginning in 2002, Dr. Kelly led the 140 member Chemistry Department which included High Throughput Screening, Computational Chemistry, Structural Biology and Medicinal Chemistry. He was subsequently promoted to Vice President; and under his leadership the department advanced a number of high-quality compounds into key proof-of-concept experiments. Several of these compounds are currently in clinical development.

Dr. Kelly received his B.S. in Chemistry from Rensselaer Polytechnic Institute, his Ph.D. in Chemistry from the University of Texas at Austin, and his MBA from New York University, Stern School of Business. After completing postdoctoral work at Yale University, he joined the Medicinal Chemistry Department at Boehringer Ingelheim Corporation, the company's U.S. headquarters based in Ridgefield, Connecticut and a member of the Boehringer Ingelheim worldwide group of companies. An inventor on 16 issued U.S. patents, Dr. Kelly is the author of more than 20 peer-reviewed publications and several book chapters.

About CoMentis
CoMentis, Inc. is headquartered in South San Francisco, CA, with research operations in both South San Francisco and Oklahoma City, OK. The company is engaged in the discovery and development of small-molecule drugs to treat Alzheimer's disease. For more information:

Contact Information

    W. Scott Harkonen, M.D.
    President and CEO
    (650) 869-7600
    Email Contact